San Diego-dependent Viking Therapeutics marked itself as a serious competitor inside the weight loss drug industry in February after revealing promising details from a mid-phase demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when presented as being a weekly injection and in March the company un